Australian Male Contraceptive Draws Little Drug Maker Interest
This article was originally published in PharmAsia News
Australian researchers say they have developed a male injectable contraceptive as effective as the pill has been for women. Trials show the testosterone-based drug that suppresses sperm output to be as much as 95 percent effective when taken four times a year. But a leading researcher said pharmaceutical companies that were involved in development have withdrawn from the project and others have shown little interest in it. The research also has drawn little interest and funding from the Australian government. (Click here for more
You may also be interested in...
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.